Literature DB >> 11838811

Corticotroph carcinoma of the pituitary: a clinicopathological study. Report of four cases.

Thomas A Gaffey1, Bernd W Scheithauer, Ricardo V Lloyd, Peter C Burger, Peter Robbins, Forouzandeh Fereidooni, Eva Horvath, Kalman Kovacs, Takao Kuroki, William F Young, Thomas J Sebo, Darren L Riehle, Allan J Belzberg.   

Abstract

To understand the relationship between pituitary adenoma and carcinoma, four adrenocorticotropic hormone-producing pituitary adenomas and corresponding metastatic carcinomas were studied. All were functional macroadenomas (three cases of Nelson syndrome and one of Cushing disease) that initially invaded the sella turcica and occurred in women ranging in age from 17 to 66 years (mean 45 years). Metastases (two craniospinal and two systemic) occurred after latency periods of 6 to 13 years. Histological specimens were immunostained for pituitary hormones, Ki-67 antigen (MIB-1), p53 and p27 proteins, D-type cyclins, and glucocorticoid receptor messenger (m)RNA. The DNA content of the specimens was assessed using Feulgen stain. Reactivities were quantified by digital image analysis. Primary/recurrent lesions and metastatic tumors differed according to their respective mean mitotic indices (1.2/10 hpf compared with 4.3/10 hpf), MIB-1 labeling (1.7% compared with 8%), p53 staining (37.3% compared with 49.9%), and p27 labeling (48% compared with 25%). Cyclin D, immunoreactivity provided no prognostically significant information. Glucocorticoid receptor mRNA was detected in all cases. Results of a ploidy analysis were variable and nonprognostic. In keeping with the 2000 World Health Organization classification of endocrine neoplasms, our findings support the concept that primary tumors that exhibit mitotic activity, an increased (> 3%) MIB-1 labeling index, and/or p53 immunoreactivity should be termed "atypical adenomas" to denote their aggressive potential and the possibility of future malignant transformation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11838811     DOI: 10.3171/jns.2002.96.2.0352

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  21 in total

Review 1.  Corticotroph pituitary carcinoma: case report and literature review.

Authors:  D J Holthouse; P D Robbins; R Kahler; N Knuckey; P Pullan
Journal:  Endocr Pathol       Date:  2001       Impact factor: 3.943

2.  Pathological changes after radiotherapy for primary pituitary carcinoma: a case report.

Authors:  Hideomi Yamashita; Keiichi Nakagawa; Masao Tago; Naoki Nakamura; Kenshiro Shiraishi; Naoko Yamauchi; Kuni Ohtomo
Journal:  J Neurooncol       Date:  2005-11       Impact factor: 4.130

Review 3.  Pituitary tumors: prognostic indicators.

Authors:  Wolfgang Saeger
Journal:  Endocrine       Date:  2005-10       Impact factor: 3.633

4.  Invasive giant prolactinoma with loss of therapeutic response to cabergoline: expression of angiogenic markers.

Authors:  María Susana Mallea-Gil; Carolina Cristina; María Inés Perez-Millan; Ana M Rodriguez Villafañe; Carolina Ballarino; Graciela Stalldecker; Damasia Becu-Villalobos
Journal:  Endocr Pathol       Date:  2009       Impact factor: 3.943

5.  An Institutional Experience of Tumor Progression to Pituitary Carcinoma in a 15-Year Cohort of 1055 Consecutive Pituitary Neuroendocrine Tumors.

Authors:  Omalkhaire M Alshaikh; Sylvia L Asa; Ozgur Mete; Shereen Ezzat
Journal:  Endocr Pathol       Date:  2019-06       Impact factor: 3.943

6.  P53 gene mutations in pituitary carcinomas.

Authors:  Yoshinori Tanizaki; Long Jin; Bernd W Scheithauer; Kalman Kovacs; Federico Roncaroli; Ricard V Lloyd
Journal:  Endocr Pathol       Date:  2007       Impact factor: 3.943

Review 7.  Best Practice No 172: pituitary gland pathology.

Authors:  J W Ironside
Journal:  J Clin Pathol       Date:  2003-08       Impact factor: 3.411

Review 8.  Malignant pituitary corticotroph adenomas: report of two cases and a comprehensive review of the literature.

Authors:  Agatha A van der Klaauw; Tina Kienitz; Christian J Strasburger; Johannes W A Smit; Johannes A Romijn
Journal:  Pituitary       Date:  2009       Impact factor: 4.107

9.  Extremely late development of pituitary carcinoma after surgery and radiotherapy.

Authors:  Eberval Gadelha Figueiredo; Wellingson Silva Paiva; Manoel Jacobsen Teixeira
Journal:  J Neurooncol       Date:  2008-11-26       Impact factor: 4.130

10.  Atypical pituitary adenoma with malignant features.

Authors:  Adam N Mamelak; John D Carmichael; Patricia Park; Sergei Bannykh; Xuemo Fan; H Vivien Bonert
Journal:  Pituitary       Date:  2011-03       Impact factor: 4.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.